AR103838A1 - Variantes de protoxina-ii y métodos de uso - Google Patents

Variantes de protoxina-ii y métodos de uso

Info

Publication number
AR103838A1
AR103838A1 ARP160100558A ARP160100558A AR103838A1 AR 103838 A1 AR103838 A1 AR 103838A1 AR P160100558 A ARP160100558 A AR P160100558A AR P160100558 A ARP160100558 A AR P160100558A AR 103838 A1 AR103838 A1 AR 103838A1
Authority
AR
Argentina
Prior art keywords
menor
aproximadamente
protoxin
donde
variants
Prior art date
Application number
ARP160100558A
Other languages
English (en)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR103838A1 publication Critical patent/AR103838A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere a variantes de Protoxina-II, polinucleótidos que las codifican y a métodos para prepara y usar lo anterior. Reivindicación 1: Una variante de Protoxina-II aislada, en donde la variante de Protoxina-II inhibe la actividad de Nav1.7 humano con un valor de lC₅₀ de aproximadamente 1 x 10⁻⁷ M ᵒ ᵐᵉⁿᵒʳ, ᵃᵖʳᵒˣⁱᵐᵃᵈᵃᵐᵉⁿᵗᵉ ¹ ˣ ¹⁰⁻⁸ M ᵒ ᵐᵉⁿᵒʳ, ᵃᵖʳᵒˣⁱᵐᵃᵈᵃᵐᵉⁿᵗᵉ ¹ ˣ ¹⁰⁻⁹ M ᵒ ᵐᵉⁿᵒʳ, ᵃᵖʳᵒˣⁱᵐᵃᵈᵃᵐᵉⁿᵗᵉ ¹ ˣ ¹⁰⁻¹⁰ M ᵒ ᵐᵉⁿᵒʳ, ᵃᵖʳᵒˣⁱᵐᵃᵈᵃᵐᵉⁿᵗᵉ ¹ ˣ ¹⁰⁻¹¹ M ᵒ ᵐᵉⁿᵒʳ ᵒ ᵃᵖʳᵒˣⁱᵐᵃᵈᵃᵐᵉⁿᵗᵉ ¹ ˣ ¹⁰⁻¹² M ᵒ ᵐᵉⁿᵒʳ, ᵉⁿ ᵈᵒⁿᵈᵉ ᵉˡ ᵛᵃˡᵒʳ ᵈᵉ ˡC₅₀ se mide con el uso de un ensayo de despolarización de membrana FLlPR® Tetra con el uso de transferencia de emergía por resonancia de fluorescencia (FRET) en presencia de 25 x 10⁻⁶ M ᵈᵉ ³⁻ᵛᵉʳᵃᵗʳᵒⁱˡᵛᵉʳᵃᶜᵉᵛⁱⁿᵃ ᵉⁿ ᶜéˡᵘˡᵃˢ HEK²⁹³ qᵘᵉ ᵉˣᵖʳᵉˢᵃⁿ ᵉˢᵗᵃᵇˡᵉᵐᵉⁿᵗᵉ Nᵃᵛ¹.⁷ ʰᵘᵐᵃⁿᵒ, ᵉⁿ ᵈᵒⁿᵈᵉ ˡᵃ ᵛᵃʳⁱᵃⁿᵗᵉ ᵈᵉ Pʳᵒᵗᵒˣⁱⁿᵃ⁻II ᵗⁱᵉⁿᵉ ᵘⁿᵃ ˢᵘˢᵗⁱᵗᵘᶜⁱóⁿ W⁷Q ʸ/ᵒ W³⁰L, ᵉⁿ ᵈᵒⁿᵈᵉ ˡᵒˢ ʳᵉˢⁱᵈᵘᵒˢ ˢᵉ ⁿᵘᵐᵉʳᵃⁿ ᵈᵉ ᵃᶜᵘᵉʳᵈᵒ ᶜᵒⁿ ˡᵃ ˢᵉᶜ. ᶜᵒⁿ ⁿúᵐ. ᵈᵉ ⁱᵈᵉⁿᵗ.: ¹.
ARP160100558A 2015-03-03 2016-03-03 Variantes de protoxina-ii y métodos de uso AR103838A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562127339P 2015-03-03 2015-03-03

Publications (1)

Publication Number Publication Date
AR103838A1 true AR103838A1 (es) 2017-06-07

Family

ID=56849056

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100558A AR103838A1 (es) 2015-03-03 2016-03-03 Variantes de protoxina-ii y métodos de uso

Country Status (15)

Country Link
US (3) US20160257726A1 (es)
EP (1) EP3265476A4 (es)
JP (2) JP2018512123A (es)
KR (1) KR20170120703A (es)
CN (1) CN107531769A (es)
AR (1) AR103838A1 (es)
AU (2) AU2016226443B2 (es)
BR (1) BR112017018834A2 (es)
CA (1) CA2978435A1 (es)
HK (1) HK1249118A1 (es)
IL (2) IL254273A0 (es)
MA (1) MA41642A (es)
MX (1) MX2017011223A (es)
TW (1) TW201706292A (es)
WO (1) WO2016140859A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
CA2926052A1 (en) 2013-10-03 2015-04-09 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
CA3009221A1 (en) 2014-12-23 2016-06-30 Automed Pty Ltd Delivery apparatus, system and associated methods
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
CN107921089A (zh) * 2015-04-02 2018-04-17 詹森生物科技公司 原毒素‑ii变体及使用方法
CN109369784B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 PaTx-1毒素及其应用
CN109369785B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 Ccotx1毒素及其应用
US11957542B2 (en) * 2020-04-30 2024-04-16 Automed Patent Holdco, Llc Sensing complete injection for animal injection device
CN114957431B (zh) * 2022-06-27 2023-06-20 四川丽妍工坊生物科技有限公司 一种皮肤抗皱多肽Cj2a2、制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
AU742270B2 (en) 1997-04-16 2001-12-20 Enteris Biopharma, Inc. Direct expression of peptides into culture media
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
WO1999014318A1 (en) 1997-09-16 1999-03-25 Board Of Regents, The University Of Texas System Method for the complete chemical synthesis and assembly of genes and genomes
EP1348466A3 (en) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2007056326A2 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
WO2008031045A2 (en) 2006-09-08 2008-03-13 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
WO2008033564A1 (en) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
US7825093B2 (en) 2006-10-25 2010-11-02 Amgen Inc. Methods of using OSK1 peptide analogs
WO2010028089A2 (en) 2008-09-03 2010-03-11 Arbor Vita Corporation Agents and methods for treatment of pain
JPWO2010104115A1 (ja) 2009-03-10 2012-09-13 独立行政法人産業技術総合研究所 膜タンパク質を特異的に認識するポリペプチドの調製方法
BR112012005860A2 (pt) 2009-09-15 2017-01-31 Alomone Preclinical Ltd peptídeos isolados do veneno de aranha, e usos dos mesmos
US9279003B2 (en) * 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CN101979411A (zh) 2010-10-21 2011-02-23 湖南师范大学 虎纹捕鸟蛛蛋白酶抑制剂
KR20140009311A (ko) 2011-01-18 2014-01-22 암젠 인크 Nav1.7 넉아웃 마우스 및 이의 용도
EP3973981A1 (en) 2012-05-18 2022-03-30 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US9102751B2 (en) * 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
WO2014016673A1 (en) 2012-07-27 2014-01-30 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
CN104065367B (zh) 2013-03-20 2017-11-07 江苏多维科技有限公司 一种低功耗磁电阻开关传感器
CA2926052A1 (en) * 2013-10-03 2015-04-09 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
CN107921089A (zh) 2015-04-02 2018-04-17 詹森生物科技公司 原毒素‑ii变体及使用方法

Also Published As

Publication number Publication date
MX2017011223A (es) 2018-06-20
US10995125B2 (en) 2021-05-04
EP3265476A2 (en) 2018-01-10
IL282482A (en) 2021-06-30
AU2021200400A1 (en) 2021-03-18
BR112017018834A2 (pt) 2018-04-17
WO2016140859A2 (en) 2016-09-09
IL254273A0 (en) 2017-10-31
MA41642A (fr) 2018-01-09
KR20170120703A (ko) 2017-10-31
AU2016226443A1 (en) 2017-09-21
HK1249118A1 (zh) 2018-10-26
US20160257726A1 (en) 2016-09-08
US20170334959A1 (en) 2017-11-23
US20210363204A1 (en) 2021-11-25
WO2016140859A3 (en) 2016-10-27
TW201706292A (zh) 2017-02-16
CN107531769A (zh) 2018-01-02
CA2978435A1 (en) 2016-09-09
AU2016226443B2 (en) 2020-10-22
JP2022071050A (ja) 2022-05-13
EP3265476A4 (en) 2018-08-22
JP2018512123A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
AR103838A1 (es) Variantes de protoxina-ii y métodos de uso
CL2016000837A1 (es) “formas isoméricas especificas del 7-hidroxi-6,8-dioxo-n-(2,4,6-triflúorobencil)-1,2,3,4,6,8,12,12a-octahidro-1,4-metanodipirido[1,2-a:1’,2’-d]pirazina-9-carboxamida; composición farmacéutica que los comprende; y su uso en el tratamiento de una infección por vih”.
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
CL2012002080A1 (es) Una combinación que comprende (4r,12as)-n-[2,4-fluoro-fenil)-metil]-3,4,6,8,12,12a-hexahidro-7-hidroxi-4-metil-6,8-dioxo-2h-pirido-{1',2':4,5]-pirazino-[2,1-b][1,3]-oxazin-9-carboxamida (gsk1349572) y uno o mas del grupo: abacavir, efavirenz y lopinavir, adicionalmente puede contener lamivudina, útil para el tratamiento del vih.
CL2014000311A1 (es) Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2013001339A1 (es) Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CR11196A (es) Compuestos quimicos
CL2013000727A1 (es) Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c.
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
GT201400111A (es) Triazolopiridinas sustituidas
DOP2014000170A (es) Compuestos de imidazopirrolidinona
CL2014001641A1 (es) Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral.
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112017002370A2 (pt) indóis para uso na infecção pelo vírus da gripe
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
CL2014001599A1 (es) Compuestos derivados de nucleosidos sustituidos en 4’-azido, 3’-fluoro o sus sales, como inhibidores de la replicacion del rna del vhc; composicion farmaceutica que los comprende; y su uso para el tratamiento o la profilaxis de la infeccion por el virus de la hepatitis c (vhc).
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
CL2013000881A1 (es) Combinaciones farmacéuticas que comprenden un componente (a) que corresponden a compuestos derivados de difenilurea omega-carboxiaril-sustituidos, (b) compuestos derivados de n-(2-arilamino)arilsulfonamida y (c) que son uno o más agentes farmaceuticos adicionales; y su uso en el tratamiento del cancer